Jacoline E. C. Bromberg

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text

Medicine, Molecular Biology, Oncology +17

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. · The Lancet Oncology · 2016 · 498 citations · Full text

Medicine, Oncology, Pharmacology +16

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

Walter Taal, Dieta Brandsma, Hein G. de Bruin et al. · Cancer · 2008 · 464 citations · Full text

Medicine, Oncology, Radiation Oncology +10

Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.

Valerie P. Castle, Kathleen P. Heidelberger, Jacoline E. C. Bromberg et al. · PubMed · 1993 · 258 citations

Medicine, Cancer Biology, Oncology +14